AngioDynamics, Inc. (NASDAQ:ANGO) Receives Consensus Recommendation of “Hold” from Brokerages

Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have received an average rating of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, two have issued a buy rating and one has issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $19.50.

A number of analysts have weighed in on the company. Zacks Research cut AngioDynamics from a “hold” rating to a “strong sell” rating in a research report on Thursday, July 16th. Canaccord Genuity Group boosted their target price on AngioDynamics from $16.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, July 15th. Weiss Ratings restated a “sell (d-)” rating on shares of AngioDynamics in a research note on Friday, July 17th. Wall Street Zen raised AngioDynamics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, HC Wainwright lifted their price objective on shares of AngioDynamics from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, July 15th.

Insider Activity at AngioDynamics

In other news, SVP Warren Nighan, Jr. sold 23,370 shares of the firm’s stock in a transaction on Thursday, July 30th. The shares were sold at an average price of $14.72, for a total value of $344,006.40. Following the completion of the sale, the senior vice president owned 64,745 shares in the company, valued at approximately $953,046.40. This trade represents a 26.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 6.00% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. acquired a new stake in AngioDynamics in the second quarter valued at about $49,480,000. Kotler Kevin acquired a new position in AngioDynamics during the 4th quarter worth approximately $21,997,000. Weber Capital Management LLC ADV acquired a new position in AngioDynamics during the 2nd quarter worth approximately $17,649,392,000. Paradigm Capital Management Inc. NY purchased a new position in shares of AngioDynamics during the 2nd quarter worth approximately $8,732,000. Finally, UBS Group AG raised its stake in shares of AngioDynamics by 83.6% during the 3rd quarter. UBS Group AG now owns 1,102,488 shares of the medical instruments supplier’s stock worth $12,315,000 after buying an additional 501,881 shares in the last quarter. 89.43% of the stock is owned by hedge funds and other institutional investors.

AngioDynamics Stock Performance

NASDAQ ANGO opened at $15.95 on Wednesday. The firm’s fifty day moving average is $14.11 and its two-hundred day moving average is $12.14. AngioDynamics has a one year low of $9.39 and a one year high of $16.29. The firm has a market cap of $659.21 million, a PE ratio of -18.33 and a beta of 0.33.

AngioDynamics (NASDAQ:ANGO) last announced its earnings results on Tuesday, July 14th. The medical instruments supplier reported ($0.07) earnings per share for the quarter, topping the consensus estimate of ($0.11) by $0.04. AngioDynamics had a negative net margin of 11.48% and a negative return on equity of 5.73%. The business had revenue of $86.61 million during the quarter, compared to the consensus estimate of $80.24 million. AngioDynamics has set its FY 2027 guidance at -0.290–0.240 EPS. Research analysts predict that AngioDynamics will post -0.25 earnings per share for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company’s products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.

In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.